Medtronic reported adjusted earnings per share of $1.45 and revenue of $9.80 billion for the quarter, both ahead of the consensus outlook. Management followed the release by raising fiscal 2027 guidance, but the headline performance included a calendar anomaly - an additional selling week that contributed roughly $570 million - complicating the interpretation of growth trends.
Market snapshot and immediate results
As of Tue, Sep 1, 2026 at 3:35 PM EDT, Medtronic PLC (ticker MDT) was trading at $92.32, with a market capitalization of $116.03 billion. The quarter produced adjusted EPS of $1.45 versus the $1.39 expected figure, and revenue of $9.80 billion versus the $9.55 billion consensus. The company’s reported results imply a fair value upside of 6.4% at that market snapshot.
Disentangling the beat - quality of growth
On the surface, revenue growth looked robust: organic revenue rose 13.7%. However, management attributed approximately 670 basis points of that increase to the extra selling week. When that time-shifted revenue is excluded, underlying growth was about 7%. Even adjusted for the calendar benefit, this roughly 7% organic gain represents the strongest comparable performance in nearly eight years outside of COVID-related distortions.
Where growth came from
Cardiovascular businesses led the expansion. Cardiac Ablation Solutions posted exceptional growth of 88%, while Cardiac Rhythm Management grew 15% and gained 80 basis points of global share. Other segments also contributed: Neuroscience revenue rose 9.3%, Medical Surgical increased 10.2%, and the diabetes business delivered 14.9% organic growth. The breadth across franchises reduces reliance on a single product cycle to drive results.
Margins were essentially stable. Adjusted gross margin reached 65.2% and adjusted operating margin reached 23.7% - each expanding only 10 basis points year over year. This indicates that the quarter’s story was driven primarily by revenue expansion rather than material operating leverage.
Guidance and its interpretation
Management nudged full-year fiscal 2027 organic-growth guidance to a range of 7.25%–7.75%, up from 6.75%–7.25%. Adjusted EPS guidance was adjusted to $5.94–$6.00. The midpoint of the updated EPS range, $5.97, sits only slightly above consensus of $5.95. For the coming quarter, Medtronic guided to adjusted EPS of $1.32–$1.34, which trails the $1.35 consensus estimate.
Upcoming catalysts to watch
- Q2 earnings - Medtronic is scheduled to report on Nov 24, 2026 during the open market. Consensus expectations for that quarter are $1.35 in EPS and $9.49 billion in revenue.
- Investor Day - An investor day is planned for Dec 10–11, 2026 and may provide further detail on long-term growth assumptions, margin targets, robotics adoption, and capital-allocation priorities.
- Diabetes separation - Management remains committed to completing the MiniMed separation before the fiscal year-end. While separation could clarify valuation over time, the restructuring carries the potential for near-term operational noise.
- Product cycle signals - Key pipeline and product adoption milestones include Affera expansion, Hugo robotics adoption, renal denervation, and new structural-heart technologies, which together will serve as primary proof points for future growth.
Bull and bear considerations
The bull case rests on broadening growth, accelerating electrophysiology momentum, and a valuation that, on certain measures, appears reasonable. As of Apr 30, 2026, Medtronic’s forward price-to-earnings ratio stood at 15.2x, and the company offered a 3.2% dividend yield as of Sep 1, 2026.
The bear case highlights margin pressure and leverage. Reported gross margin has declined from 68.4% in fiscal 2022 to 65.3% in fiscal 2026, and total debt was $29.15 billion as of Apr 24, 2026. Executing through competition, securing product approvals, and managing the diabetes separation are cited as material execution risks. Analyst targets cited included a $110 target from TD Cowen and a $100 target raised by BTIG.
Conclusion
The quarter provided evidence that momentum exists across several franchises, but the presence of an extra selling week means the true test of sustainability will arrive with upcoming periods. Q2 results and the company’s investor-day disclosures will be the next opportunities for investors to judge whether organic growth and margin trends can persist absent the calendar boost.